Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beraprost sodium in pulmonary arterial hypertension with left ventricular systolic dysfunction
ChiCTR-IPR-17012961Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of beraprost in Pulmonary Hypertension Associated With Systolic Heart Failure (PH-HFrEF) and left ventricular systolic dysfunction (LVSD) (2 arms), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: Pulmonary artery pressure at 12 months, Left ventricular ejection fraction at 12 months and 2 more. Started Oct 2017; status: recruiting.
02
Drugs
beraprost
03
Conditions
Pulmonary Hypertension Associated With Systolic Heart Failure (PH-HFrEF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on ChiCTR-IPR-17012961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012961.